PepGen Inc. 8-K

What Happened
On March 30, 2026, PepGen Inc. announced topline results from the lowest-dose (5 mg/kg) multiple-ascending-dose (MAD) cohort in its ongoing Phase 2 FREEDOM2 study. The company said the 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data. PepGen furnished a press release (Exhibit 99.1) and filed a presentation titled “FREEDOM2‑DM1, 5 mg/kg Cohort Data Update” (Exhibit 99.2) that it will use in investor meetings. The 8‑K reports Regulation FD disclosure (Item 7.01) and Other Events (Item 8.01).

Key Details

• Date filed: March 30, 2026 (press release and presentation furnished as Exhibits 99.1 and 99.2).
• Study: Phase 2 FREEDOM2, lowest MAD cohort at 5 mg/kg.
• Reported outcomes: favorable safety profile plus positive splicing and vHOT (validated human outcome tool) data at this dose.
• Company will use the presentation in meetings with investors; no new financial results or regulatory filings were reported in this 8‑K.

Why It Matters
Positive topline safety and biomarker (splicing and vHOT) signals at the lowest tested dose can reduce clinical risk and support continued development of PepGen’s FREEDOM2 program. For investors, these results are material program updates—useful for assessing clinical progress—but the filing does not include detailed data tables, next steps, timelines, or financial impacts. Investors should watch for forthcoming detailed data releases, regulatory updates, or guidance from the company.